COVID-19
Conditions
Brief summary
This study was a multicenter, non-intervention, real world study. To evaluate the efficacy and safety of azvudine in nursing homes with mild/common COVID-19 patients. The primary outcome measure was the proportion of patients with severe/critical illness within 28 days.
Interventions
DRUGAzvudine
Azvudine tablets are taken orally 5mg daily for a maximum of 14 days
Sponsors
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Huashan Hospital
Shanghai Henlius Biotech
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Living in a nursing home who has taken or intends to take azvudine tablets depending on their condition; 2. Mild/normal subjects who are SARS-CoV-2 RT-RCR positive or antigen-positive; 3. Subjects have at least one or more of the following clinical symptoms of COVID-19 in the 24 hours prior to initial administration, including but not limited to: fever, cough, sore throat, stuffy or runny nose, headache, muscle pain, nausea, vomiting, diarrhea, shortness of breath or difficulty breathing, chills or chills; 4. Volunteer to participate in the experiment and sign the informed consent in person or complete the informed consent over the phone.
Exclusion criteria
1. Subjects have received antiviral therapy, such as Paxlovid and SARS-CoV-2 monoclonal antibody therapy (except previous treatment for COVID-19 infection) before entering the study; 2. Shortness of breath, RR≥30 times/min or resting state, oxygen saturation of finger when sucking air ≤93%; 3. Mechanical ventilation is required or expected to be urgently required; 4. Severe infections requiring systemic treatment within 14 days prior to initial medication; 5. Use of other antiviral drugs (such as anti-HIV, hepatitis B, and hepatitis C drugs) within 14 days prior to the first medication.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of patients with severe/critical illness within 28 days | up to 28 days from the first dose of Azvudine for treatment SARS-CoV-2 infection |
Secondary
| Measure | Time frame |
|---|---|
| all-cause mortality within 28 days | up to 28 days from the first dose of Azvudine for treatment SARS-CoV-2 infection |
| Proportion of hospitalization within 28 days and the duration of hospitalization | up to 28 days from the first dose of Azvudine for treatment SARS-CoV-2 infection |
Outcome results
None listed